Curative Biotechnology, Inc. (CUBT)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.93 Million USD | 56.47% |
| 2022 | -4.43 Million USD | 11.46% |
| 2021 | -5.01 Million USD | -8.17% |
| 2020 | -4.63 Million USD | -84943.83% |
| 2019 | -5451.00 USD | 0.0% |
| 2018 | -5451.00 USD | 23.24% |
| 2017 | -7101.00 USD | -367.79% |
| 2016 | -1518.00 USD | 98.26% |
| 2015 | -87.15 Thousand USD | -34.08% |
| 2014 | -65 Thousand USD | -65.79% |
| 2013 | -39.2 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -707.82 Thousand USD | -29.32% |
| 2024 Q2 | -571.22 Thousand USD | 19.3% |
| 2023 Q1 | -654.84 Thousand USD | 40.85% |
| 2023 FY | -1.93 Million USD | 56.47% |
| 2023 Q4 | -547.36 Thousand USD | 17.96% |
| 2023 Q3 | -667.18 Thousand USD | -955.0% |
| 2023 Q2 | -63.24 Thousand USD | 90.34% |
| 2022 FY | -4.43 Million USD | 11.46% |
| 2022 Q4 | -1.1 Million USD | -2.45% |
| 2022 Q3 | -1.08 Million USD | -12.17% |
| 2022 Q2 | -963.37 Thousand USD | 25.23% |
| 2022 Q1 | -1.28 Million USD | -37.66% |
| 2021 FY | -5.01 Million USD | -8.17% |
| 2021 Q4 | -935.93 Thousand USD | -8.04% |
| 2021 Q2 | -2.58 Million USD | -314.47% |
| 2021 Q1 | -624.34 Thousand USD | 86.31% |
| 2021 Q3 | -866.3 Thousand USD | 66.52% |
| 2020 Q2 | -18.97 Thousand USD | -19.68% |
| 2020 Q1 | -15.85 Thousand USD | -975.05% |
| 2020 FY | -4.63 Million USD | -84943.83% |
| 2020 Q4 | -4.56 Million USD | -60611.51% |
| 2020 Q3 | -7513.00 USD | 60.41% |
| 2019 Q4 | -1475.00 USD | -11.32% |
| 2019 FY | -5451.00 USD | 0.0% |
| 2019 Q3 | -1325.00 USD | 74.98% |
| 2019 Q2 | -5296.00 USD | 0.0% |
| 2019 Q1 | -5296.00 USD | 0.0% |
| 2018 FY | -5451.00 USD | 23.24% |
| 2017 FY | -7101.00 USD | -367.79% |
| 2016 FY | -1518.00 USD | 98.26% |
| 2015 FY | -87.15 Thousand USD | -34.08% |
| 2014 FY | -65 Thousand USD | -65.79% |
| 2014 Q1 | -47.41 Thousand USD | -404.34% |
| 2013 Q1 | -17.21 Thousand USD | 0.0% |
| 2013 Q4 | -9402.00 USD | 0.0% |
| 2013 FY | -39.2 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -44.718% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 61.689% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 89.171% |
| Nascent Biotech, Inc. | -2.22 Million USD | 13.331% |
| Rebus Holdings, Inc. | -664 Thousand USD | -191.056% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.361% |
| Qrons Inc. | -643.67 Thousand USD | -200.245% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -396.088% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 96.518% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -365.152% |
| Skye Bioscience, Inc. | -13.67 Million USD | 85.864% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.308% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 139.322% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -638.41% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.451% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 32.201% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -25.817% |
| Mesoblast Limited | -84.14 Million USD | 97.703% |
| Marizyme, Inc. | -34.08 Million USD | 94.33% |
| Genus plc | 6.4 Million USD | 130.197% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 119.837% |
| Pharming Group N.V. | -4.87 Million USD | 60.394% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 2.712% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -107.5% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 76.855% |
| ContraFect Corporation | -56.88 Million USD | 96.603% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 57.569% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -37.848% |
| IMV Inc. | -38.67 Million USD | 95.002% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 29.745% |
| MultiCell Technologies, Inc. | -722.81 USD | -267274.552% |
| ONE Bio Corp. | 13.68 Million USD | 114.126% |
| Accustem Sciences Inc. | -3.74 Million USD | 48.414% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.724% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -300.075% |
| Q BioMed Inc. | -3.44 Million USD | 43.911% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 154.594% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 26.447% |
| Biomind Labs Inc. | -1 Million USD | -91.423% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 96.484% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 33.387% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 70.93% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -3.66% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -6352.357% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 87.822% |
| GB Sciences, Inc. | -1.42 Million USD | -36.051% |
| Alpha Cognition Inc. | -9.7 Million USD | 80.088% |
| HST Global, Inc. | -140.9 Thousand USD | -1271.55% |
| CSL Limited | 3.7 Billion USD | 100.052% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -71.802% |
| Halberd Corporation | -75.05 Thousand USD | -2475.097% |
| Enzolytics Inc. | -2.14 Million USD | 10.061% |
| Agentix Corp. | -1.37 Million USD | -40.886% |
| Resverlogix Corp. | -12.74 Million USD | 84.841% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 39.001% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.545% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -85.116% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 33.802% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -22.367% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 43.242% |
| AVAX Technologies, Inc. | 6.69 Million USD | 128.876% |
| Zenith Capital Corp. | -8.94 Million USD | 78.39% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.535% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -10993.565% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 21.289% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1026.824% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 3.599% |
| Kadimastem Ltd | -3.04 Million USD | 36.433% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -96.393% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -53.87% |
| BioStem Technologies, Inc. | -7.77 Million USD | 75.156% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -964.887% |
| LadRx Corporation | -3.82 Million USD | 49.456% |
| Cell Source, Inc. | -4.32 Million USD | 55.319% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -181.332% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -181.332% |
| NovAccess Global Inc. | -2.46 Million USD | 21.654% |
| Affymax, Inc. | -15.04 Million USD | 87.155% |
| Itoco Inc. | -919.14 Thousand USD | -110.263% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 54.403% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -72.709% |
| Mobile Lads Corp. | -554.55 Thousand USD | -248.501% |
| CytoDyn Inc. | -18.05 Million USD | 89.298% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -7578.228% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -778.148% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -242.223% |
| SYBLEU INC | -149.18 Thousand USD | -1195.489% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -6.403% |
| International Stem Cell Corporation | -663 Thousand USD | -191.495% |
| Bioxytran, Inc. | -3.82 Million USD | 49.41% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3571.372% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -9401.524% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 94.671% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -19.444% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -162.642% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 37.878% |
| Neutra Corp. | -229.48 Thousand USD | -742.147% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 88.981% |
| PureTech Health plc | -146.19 Million USD | 98.678% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 91.007% |
| IXICO plc | -1.43 Million USD | -34.489% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 79.637% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.413% |
| CSL Limited | 3.81 Billion USD | 100.051% |
| Cellectis S.A. | -108.85 Million USD | 98.225% |